Skip to main content
Premium Trial:

Request an Annual Quote

PROOF, AllerGen Team on Allergy PGx

NEW YORK (GenomeWeb News) – The Centre of Excellence for the Prevention of Organ Failure (PROOF) has teamed up with the Allergy, Genes and Environment Network of Centres of Excellence (AllerGen NCE) to develop blood-based tests intended to be used in clinical trials of drugs for allergic diseases.

The Canadian centers said they will apply PROOF's biomarker development expertise to blood samples obtained from AllerGen in an effort to identify molecular signals that predict chronic inflammatory responses in allergic asthmatic adults. The goal is to find biomarkers that can be used for effectively monitoring therapeutics being developed for allergic asthma.

The partners expects to complete the development and validation of a biomarker panel to predict an asthmatic individual's response to allergen exposure, as well as a panel to diagnose late allergic response by early 2014.

Among several partnerships it has already formed this year, Vancouver, British Columbia-based PROOF is working with Adiga Life Sciences to identify proteomic and genomic biomarkers for monitoring the effectiveness of allergy vaccines.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.